Market Scenario 

Inhaled Nitric Oxide Market globally is analyzed to reach US$ 426.88 Mn by 2031. The market was valued at US$ 246.07 Mn in 2022 and is estimated to grow at a CAGR of 6.64% during 2023-2031.

The increasing prevalence of respiratory diseases, technological advancements in healthcare, and growing demand for nitric oxide in various medical applications are some of the key factors driving the growth of the market. One of the major factors driving the growth of the inhaled nitric oxide market is the increasing prevalence of respiratory diseases. According to the World Health Organization (WHO), around 235 million people suffer from asthma worldwide, and it is one of the most common chronic diseases among children. Inhaled nitric oxide is used for the treatment of respiratory diseases, such as acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), and pulmonary hypertension. The increasing prevalence of these diseases is expected to drive the demand for inhaled nitric oxide.

Moreover, technological advancements in healthcare are also driving the growth of the inhaled nitric oxide market. The development of portable and easy-to-use devices for the delivery of inhaled nitric oxide has made it more convenient and accessible for patients. This has increased the adoption of inhaled nitric oxide in various healthcare settings, including hospitals, clinics, and home care settings. The growing demand for inhaled nitric oxide in various medical applications is also expected to drive the growth of the market. Inhaled nitric oxide is used in neonatal intensive care units (NICUs) for the treatment of persistent pulmonary hypertension of the newborn (PPHN) and in cardiac surgery for the treatment of pulmonary hypertension. It is also used in the treatment of acute respiratory distress syndrome (ARDS) and chronic obstructive pulmonary disease (COPD).

To Get more Insights,  Request A Free Sample 

Market Dynamics 

Drivers 

Increasing Prevalence of Respiratory Diseases

The increasing prevalence of respiratory diseases is a major driver of the global inhaled nitric oxide market. According to the World Health Organization (WHO), respiratory diseases are responsible for about 10% of all deaths worldwide, with more than 3 million deaths per year. The rising incidence of respiratory diseases, such as asthma, chronic obstructive pulmonary disease (COPD), and pulmonary hypertension, is expected to drive the demand for inhaled nitric oxide. Inhaled nitric oxide is an effective treatment for these diseases and can help improve patient outcomes.

Asthma is one of the most common respiratory diseases, affecting more than 339 million people worldwide. Inhaled nitric oxide is used to treat acute asthma exacerbations and can help reduce the need for hospitalization. In addition, inhaled nitric oxide has been shown to improve oxygenation and reduce pulmonary hypertension in patients with COPD, which can improve their quality of life. These factors are expected to drive the growth of the global inhaled nitric oxide market.

Technological Advancements in Healthcare

Technological advancements in healthcare are driving the growth of the global inhaled nitric oxide market. The development of portable and easy-to-use devices for the delivery of inhaled nitric oxide has made it more convenient and accessible for patients to receive treatment. These devices are smaller and more efficient than traditional delivery systems, making them ideal for use in homecare settings. In addition, the development of new and innovative delivery systems, such as the iNOvent® system, has improved the precision and accuracy of inhaled nitric oxide delivery.

Another technological advancement that is driving the growth of the market is the development of nitric oxide sensors. These sensors can be used to monitor the level of nitric oxide in a patient's breath, which can help healthcare providers determine the most effective dose of inhaled nitric oxide. This can improve patient outcomes and reduce the risk of adverse events.

Restraint: Limited Availability and High Cost of Treatment

Despite the growing demand for inhaled nitric oxide, its availability and cost remain significant restraints for the global market. Inhaled nitric oxide requires specialized equipment and trained healthcare professionals, which can limit its availability in some regions, especially in low- and middle-income countries. This can limit access to treatment for patients who need it the most.

In addition, the cost of inhaled nitric oxide treatment can be high, especially for long-term use. The cost of equipment, delivery systems, and monitoring devices can add up, making it difficult for some patients to afford treatment. The high cost can also limit the adoption of inhaled nitric oxide in some healthcare settings, such as smaller hospitals and clinics in the inhaled nitric oxide market. As a result, reducing the cost of treatment and improving its availability will be important to ensure that all patients have access to this life-saving treatment.

Segmental Analysis of the Global Inhaled Nitric Oxide Market

By System: Cylinder-Based System to Dominate Market with More Than 53% Market Share

The cylinder-based system is expected to dominate the global market with over 53% market share during the forecast period. This can be attributed to its cost-effectiveness, ease of use, and portability. The cylinder-based system is easy to set up and can be used in various healthcare settings, including hospitals, clinics, and home care settings.

Moreover, the cylinder-based system has been in use for several years and is a reliable and trusted method for delivering inhaled nitric oxide. It is widely available and can be easily sourced, making it a preferred choice for healthcare providers in developing countries. These factors are expected to drive the growth of the cylinder-based system segment in the global inhaled nitric oxide market during the forecast period.

By Application: Acute Respiratory Distress Syndrome to Capture More Than 59% Revenue Share

Acute respiratory distress syndrome (ARDS) is expected to capture more than 59% revenue share of the global inhaled nitric oxide market during the forecast period. ARDS is a serious condition that affects the lungs and can lead to respiratory failure. Inhaled nitric oxide is used as a treatment for ARDS as it helps to improve oxygenation and reduce pulmonary hypertension.

In addition, the increasing prevalence of ARDS is expected to drive the demand for inhaled nitric oxide in the coming years. According to the National Center for Biotechnology Information, ARDS affects approximately 10% of all critically ill patients and has a mortality rate of around 30-40%. The rising incidence of ARDS is expected to drive the growth of the market for the treatment of the condition.

By End User: Hospitals to Dominate with Over 85% Market Share

Hospitals are expected to dominate the global inhaled nitric oxide market with over 85% market share during the forecast period. This can be attributed to the high demand for inhaled nitric oxide in hospital settings for the treatment of respiratory diseases, such as ARDS, COPD, and pulmonary hypertension.

Hospitals have the necessary infrastructure and trained healthcare professionals to administer inhaled nitric oxide treatment, making it the preferred setting for the treatment. Moreover, hospitals have the resources to invest in advanced healthcare technologies, which has led to the hig`h adoption of inhaled nitric oxide in these settings.

Furthermore, favorable reimbursement policies for inhaled nitric oxide treatment in hospitals have also contributed to the dominance of this segment. Many countries provide reimbursement for inhaled nitric oxide treatment in hospital settings, which has helped to improve patient access to treatment and has increased the adoption of inhaled nitric oxide in these settings.

 To Understand More About this Research:  Request A Free Sample 

Regional Analysis 

Europe is poised to hold over 40% share of the global inhaled nitric oxide market during the forecast period. The region's dominance can be attributed to several factors, including the rising prevalence of respiratory diseases, increasing adoption of advanced healthcare technologies, and favorable reimbursement policies.

Respiratory diseases have emerged as a significant health concern in Europe, with the European Respiratory Society estimating that such diseases account for a third of all deaths in the region. The increasing incidence of respiratory diseases like asthma, COPD, and pulmonary hypertension has led to a corresponding rise in the demand for inhaled nitric oxide in the region.

Several prominent manufacturers in the global inhaled nitric oxide market such as Mallinckrodt Pharmaceuticals, Praxair, and Air Liquide are based in Europe, and their presence in the region has helped to improve the availability of inhaled nitric oxide. These companies have also invested in research and development activities to enhance the effectiveness of inhaled nitric oxide treatment, further boosting its adoption in the region.

Europe's advanced healthcare system has also been instrumental in driving the adoption of inhaled nitric oxide. The region's healthcare providers have a high level of awareness about the potential benefits of inhaled nitric oxide, and the availability of advanced healthcare technologies has made it easier to administer the treatment.

Moreover, favorable reimbursement policies implemented by many European countries have supported the growth of the inhaled nitric oxide market in the region. These policies cover the cost of inhaled nitric oxide treatment for patients with respiratory diseases, thereby enhancing patient access to treatment and driving its adoption.

List of Key Companies Profiled:

• Air Liquide Healthcare
• Bellerophon Therapeutics
• Beyond Air
• Circassia Pharmaceuticals
• Getinge
• International Biomedical
• LINDE
• Mallinckrodt Pharmaceuticals
• Praxair (NoxBox)
• SLE
• Vero Biotech
• Other major players

Market Segmentation Overview

By System

• Cylinder Based System
• Electric System
• Chemical Based System

By Type

• Adults
• Pediatrics

By Components

• Hardware
  • Mechanical Ventilator
  • Flow Sensor
  • Respiratory Circuits Connectors
  • Nitric Oxide Container
  • Nitric Oxide Analyzer
  • Inlet & Outlet Pipe
  • Digital Monitor
• Services
  • Managed Services
  • Professional Services
  • Consulting
  • Support & Maintenance

By Applications

• Pulmonary Hypertension
• Tuberculosis Treatment
• Malaria Treatment
• Chronic Obstructive Pulmonary Applications  (COPD)
• Acute Respiratory Distress Syndrome  (ARDS)
• Others

By End User

• Hospitals
• Clinics
• Ambulatory Centers

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • Western Europe
    • The UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Western Europe
  • Eastern Europe
    • Poland
    • Russia
    • Rest of Eastern Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East & Africa (MEA)
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of MEA
• South America
  • Argentina
  • Brazil
  • Rest of South America